🇺🇸 FDA
Patent

US 11213526

Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

granted A61KA61K31/437A61K31/444

Quick answer

US patent 11213526 (Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators) held by Corcept Therapeutics Incorporated expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/437, A61K31/444, A61K31/513, A61K31/567